![Konstantinos Efthymiopoulos](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Konstantinos Efthymiopoulos
Presidente en SynAffix BV .
Cargos activos de Konstantinos Efthymiopoulos
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
SynAffix BV
![]() SynAffix BV BiotechnologyHealth Technology SynAffix BV develops next-generation antibody-drug conjugates for targeted cancer and other diseases. The application of the firm?s proprietary GlycoConnect technology, comprising precision modification of a protein's native glycosylation site, allows the fast and simple construction of antibody-drug conjugates that are both stable and homogeneous. The company was founded by Floris van Delft and Sander van Berkel in 2010 and is headquartered in Oss, the Netherlands. | Presidente | 07/01/2016 | - |
Independent Dir/Board Member | 07/01/2016 | - |
Historial de carrera de Konstantinos Efthymiopoulos
Antiguos cargos conocidos de Konstantinos Efthymiopoulos.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Epsilon-3 Bio Ltd
![]() Epsilon-3 Bio Ltd Pharmaceuticals: OtherHealth Technology Epsilon-3 Bio Ltd. develops compounds targeting the removal of cellular debris in chronic inflammatory and autoimmune disorders. The company was founded by Martin W. Edwards, Konstantinos Efthymiopoulos, David J. Grainger and Christian De La Tour on June 18, 2010 and is headquartered in Cambridge, the United Kingdom. | Fundador | 18/06/2010 | - |
Farmitalia Carlo Erba SRL | Corporate Officer/Principal | - | - |
Glaxo, Inc. | Corporate Officer/Principal | - | - |
Glaxo Wellcome, Inc. | Corporate Officer/Principal | - | - |
Eurand, Inc.
![]() Eurand, Inc. Pharmaceuticals: MajorHealth Technology Eurand, Inc. develops pharmaceutical and biopharmaceutical products based on its proprietary drug delivery technologies. The company has had three products approved by the FDA since 2000. The company's most advanced development product, a treatment for exocrine pancreatic insufficiency associated with cystic fibrosis and other diseases, is currently undergoing Phase III clinical trials in the United States. It's technology platforms include: bioavailability enhancement of poorly soluble drugs, customized release, taste masking/fast dissolving formulations and drug conjugation. The company was founded in 1969 and is headquartered in Vandalia, OH. | Director Técnico/Científico/I+D | - | - |
Funxional Therapeutics Ltd.
![]() Funxional Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Funxional Therapeutics Ltd. is a clinical stage pharmaceutical company, which offers drug and therapeutic development programs. It specializes on anti-inflammatory therapies and compounds. The company was founded by David J. Grainger on August 8, 2011 and is headquartered in Cambridge, the United Kingdom. | Presidente | - | - |
Formación de Konstantinos Efthymiopoulos.
University of Strasbourg | Doctorate Degree |
National & Kapodistrian University of Athens | Graduate Degree |
University of London | Masters Business Admin |
Estadísticas
Internacional
Reino Unido | 4 |
Estados Unidos | 3 |
Francia | 2 |
Operativa
Corporate Officer/Principal | 3 |
Graduate Degree | 2 |
President | 1 |
Sectorial
Health Technology | 7 |
Consumer Services | 4 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas privadas | 7 |
---|---|
Funxional Therapeutics Ltd.
![]() Funxional Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Funxional Therapeutics Ltd. is a clinical stage pharmaceutical company, which offers drug and therapeutic development programs. It specializes on anti-inflammatory therapies and compounds. The company was founded by David J. Grainger on August 8, 2011 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Eurand, Inc.
![]() Eurand, Inc. Pharmaceuticals: MajorHealth Technology Eurand, Inc. develops pharmaceutical and biopharmaceutical products based on its proprietary drug delivery technologies. The company has had three products approved by the FDA since 2000. The company's most advanced development product, a treatment for exocrine pancreatic insufficiency associated with cystic fibrosis and other diseases, is currently undergoing Phase III clinical trials in the United States. It's technology platforms include: bioavailability enhancement of poorly soluble drugs, customized release, taste masking/fast dissolving formulations and drug conjugation. The company was founded in 1969 and is headquartered in Vandalia, OH. | Health Technology |
Glaxo Wellcome, Inc. | Health Technology |
Glaxo, Inc. | |
Farmitalia Carlo Erba SRL | Health Technology |
Epsilon-3 Bio Ltd
![]() Epsilon-3 Bio Ltd Pharmaceuticals: OtherHealth Technology Epsilon-3 Bio Ltd. develops compounds targeting the removal of cellular debris in chronic inflammatory and autoimmune disorders. The company was founded by Martin W. Edwards, Konstantinos Efthymiopoulos, David J. Grainger and Christian De La Tour on June 18, 2010 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
SynAffix BV
![]() SynAffix BV BiotechnologyHealth Technology SynAffix BV develops next-generation antibody-drug conjugates for targeted cancer and other diseases. The application of the firm?s proprietary GlycoConnect technology, comprising precision modification of a protein's native glycosylation site, allows the fast and simple construction of antibody-drug conjugates that are both stable and homogeneous. The company was founded by Floris van Delft and Sander van Berkel in 2010 and is headquartered in Oss, the Netherlands. | Health Technology |